Moreover, glioma patients with isocitrate dehydrogenase mutations or wild-type patients had distinct molecular mechanisms (e.g., DNA repair pathways or anti-oxidative pathways) and distinct outcomes [39]. The gene discussed is IDH3A; the disease is central nervous system cancer.